Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249555 | 0.85 | HSP90AA1 (0.44) | KDM4ELMNAHPGDMAPTHSP90AA1 | |
| SCHEMBL18249539 | 0.84 | KDM4E (0.42) | KDM4ELMNAHPGDMAPTHSP90AA1 | |
| SCHEMBL8439027 | 0.83 | SLC40A1 (0.52) | KDM4ELMNAMAPTHSP90AA1HSP90AB1 | |
| SCHEMBL18249542 | 0.83 | CHRNB2 (0.49) | KDM4ELMNAHPGDMAPTHSP90AA1 | |
| SCHEMBL454942 | 0.83 | CYP1A2 (0.55) | KDM4ELMNAMAPTHSP90AA1HSP90AB1 | |
| Bromide SCHEMBL1143538 | 0.81 | CYP1A2 (0.53) | KDM4ELMNAMAPTHSP90AA1HSP90AB1 | |
| Bromide SCHEMBL27612053 | 0.80 | CYP1A2 (0.52) | KDM4ELMNAMAPTHSP90AA1HSP90AB1 | |
| SCHEMBL12047094 | 0.79 | CYP1A2 (0.46) | KDM4ELMNAHPGDMAPTHSP90AA1 | |
| SCHEMBL2474944 | 0.77 | HSP90AA1 (0.56) | KDM4ELMNAHPGDMAPTHSP90AA1 | |
| SCHEMBL5330815 | 0.77 | CYP3A4 (0.55) | KDM4EMAPTRAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373650-B1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| EP-2373650-B1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| EP-2373650-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | Noscira, S.A. (ES) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | HTT, PFN1, PSEN1 | KDM4E 1171/4885LMNA 1060/4885HPGD 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.